Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.

Abstract:

BACKGROUND AND OBJECTIVE:A prospective study to evaluate the role of fludarabine alone or in combination with idarubicin in untreated patients with mantle cell lymphoma (MCL). DESIGN AND METHODS:Twenty-nine untreated patients with mantle cell lymphoma were stochastically treated with intravenous fludarabine at a dose of 25 mg/m(2)/day for 5 days (11 patients) or with a combination of fludarabine and idarubicin (FLU-ID) (fludarabine 25 mg/m(2) i.v. on days 1 to 3 and idarubicin 12 mg/m(2) i.v. on day 1 (18 patients). For both regimens, cycles were given at three-week intervals for a total of six courses. According to the International Prognostic Index, the most part of high-intermediate and high risk factor patients were in the FLU-ID subset: 7 (39%) patients vs. 2 (18%) in the fludarabine alone subset. RESULTS:Of the 29 patients, 8 (28%) obtained a complete response and 10 (35%) a partial response, with an overall response rate of 63%. The remaining 11 (37%) patients did not respond to the therapy. The overall response rates were 64% (7 patients) in the fludarabine group and 61% (11 patients) in the FLU-ID group. The complete response rate was 27% (3 patients) for fludarabine and 28% (5 patients) for FLU-ID. The toxicity was mild in terms of neutropenia and infections, and no fatalities occurred due to drug-induced side effects. INTERPRETATION AND CONCLUSIONS:These results suggest the efficacy of fludarabine alone or in combination with idarubicin in MCL patients. It will be important to increase this experience and to assess other fludarabine-containing regimens, in particular with cyclophosphamide plus idarubicin and with mitoxantrone and or cyclophosphamide, to test the true role of this approach in MCL.

journal_name

Haematologica

journal_title

Haematologica

authors

Zinzani PL,Magagnoli M,Moretti L,Battista R,Ronconi F,De Renzo A,Zaccaria A,Gentilini P,Guardigni L,Gherlinzoni F,Cellini C,Fattori PP,Bendandi M,Bocchia M,Aitini E,Tura S

keywords:

subject

Has Abstract

pub_date

1999-11-01 00:00:00

pages

1002-6

issue

11

eissn

0390-6078

issn

1592-8721

journal_volume

84

pub_type

临床试验,杂志文章
  • Rituximab and dose dense chemotherapy in primary breast lymphoma.

    abstract::Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87%), event free-surviva...

    journal_title:Haematologica

    pub_type: 临床试验,信件

    doi:10.3324/haematol.10892

    authors: Avilés A,Castañeda C,Neri N,Cleto S,Nambo MJ

    更新日期:2007-08-01 00:00:00

  • Provision of phenotype-matched blood units: no need for pre-transfusion antibody screening.

    abstract:BACKGROUND AND OBJECTIVES:The Hong Kong government is planning to introduce an electronic smart identity card for all seven million citizens in 2003. If the smart card contains the full red cell phenotype/genotype of the individual, it may be possible to transfuse phenotype-matched blood units without pre-transfusion a...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Lau FY,Wong R,Chan NP,Chui CH,Ng E,Ng MH,Cheng G

    更新日期:2001-07-01 00:00:00

  • Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.

    abstract::Although myelodysplastic syndromes are heterogeneous disorders comprising a benign subset of bone marrow failure similar to aplastic anemia, no laboratory test has been established to distinguish it from bone marrow failures that can evolve into acute myeloid leukemia. Plasma thrombopoietin levels were measured in 120...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.066217

    authors: Seiki Y,Sasaki Y,Hosokawa K,Saito C,Sugimori N,Yamazaki H,Takami A,Nakao S

    更新日期:2013-06-01 00:00:00

  • Enhanced alternative splicing of the FLVCR1 gene in Diamond Blackfan anemia disrupts FLVCR1 expression and function that are critical for erythropoiesis.

    abstract:BACKGROUND:Diamond-Blackfan anemia is a fatal congenital anemia characterized by a specific disruption in erythroid progenitor cell development. Approximately 25% of patients have mutations in the ribosomal protein RPS19 suggesting that Diamond-Blackfan anemia may be caused by a defect in ribosome biogenesis and transl...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.13359

    authors: Rey MA,Duffy SP,Brown JK,Kennedy JA,Dick JE,Dror Y,Tailor CS

    更新日期:2008-11-01 00:00:00

  • Impaired killing of Candida albicans by granulocytes mobilized for transfusion purposes: a role for granule components.

    abstract::Granulocyte transfusions are used to treat neutropenic patients with life-threatening bacterial or fungal infections that do not respond to anti-microbial drugs. Donor neutrophils that have been mobilized with granulocyte-colony stimulating factor (G-CSF) and dexamethasone are functional in terms of antibacterial acti...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2015.136630

    authors: Gazendam RP,van de Geer A,van Hamme JL,Tool AT,van Rees DJ,Aarts CE,van den Biggelaar M,van Alphen F,Verkuijlen P,Meijer AB,Janssen H,Roos D,van den Berg TK,Kuijpers TW

    更新日期:2016-05-01 00:00:00

  • High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

    abstract::It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this study, we analyzed the outcome of 84 patients at 3 years of follow-up ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.204891

    authors: García-Marco JA,Jiménez JL,Recasens V,Zarzoso MF,González-Barca E,De Marcos NS,Ramírez MJ,Parraga FJP,Yañez L,De La Serna Torroba J,Malo MDG,Ariznavarreta GD,Persona EP,Guinaldo MAR,De Paz Arias R,Llanos EB,Jarque I,Val

    更新日期:2019-11-01 00:00:00

  • Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

    abstract:BACKGROUND:The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. DESIGN AND METHODS:In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.012088

    authors: Todoerti K,Barbui V,Pedrini O,Lionetti M,Fossati G,Mascagni P,Rambaldi A,Neri A,Introna M,Lombardi L,Golay J

    更新日期:2010-02-01 00:00:00

  • MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation.

    abstract::MicroRNA-34b down-regulation in acute myeloid leukemia was previously shown to induce CREB overexpression, thereby causing leukemia proliferation in vitro and in vivo. The role of microRNA-34b and CREB in patients with myeloid malignancies has never been evaluated. We examined microRNA-34b expression and the methylati...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.070664

    authors: Pigazzi M,Manara E,Bresolin S,Tregnago C,Beghin A,Baron E,Giarin E,Cho EC,Masetti R,Rao DS,Sakamoto KM,Basso G

    更新日期:2013-04-01 00:00:00

  • Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.

    abstract::The mechanisms of drug resistance in multiple myeloma are poorly understood. Here we show that CD47, an integrin-associated receptor, is significantly upregulated in drug resistant myeloma cells in comparison with parental cells, and that high expression of CD47 detected by immunohistochemistry is associated with shor...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.227579

    authors: Rastgoo N,Wu J,Liu A,Pourabdollah M,Atenafu EG,Reece D,Chen W,Chang H

    更新日期:2020-12-01 00:00:00

  • Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.

    abstract::Long non-coding ribonucleic acids (RNAs) are a novel class of RNA molecules, which are increasingly recognized as important molecular players in solid and hematologic malignancies. Herein we investigated whether long non-coding RNA expression is associated with clinical and molecular features, as well as outcome of yo...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2017.166215

    authors: Papaioannou D,Nicolet D,Volinia S,Mrózek K,Yan P,Bundschuh R,Carroll AJ,Kohlschmidt J,Blum W,Powell BL,Uy GL,Kolitz JE,Wang ES,Eisfeld AK,Orwick SJ,Lucas DM,Caligiuri MA,Stone RM,Byrd JC,Garzon R,Bloomfield CD

    更新日期:2017-08-01 00:00:00

  • In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

    abstract::Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells ex...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2014.111740

    authors: Angelot-Delettre F,Roggy A,Frankel AE,Lamarthee B,Seilles E,Biichle S,Royer B,Deconinck E,Rowinsky EK,Brooks C,Bardet V,Benet B,Bennani H,Benseddik Z,Debliquis A,Lusina D,Roussel M,Solly F,Ticchioni M,Saas P,Garna

    更新日期:2015-02-01 00:00:00

  • Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.

    abstract:BACKGROUND:Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and a poor tolerance of methotrexate. This latter problem is assumed to be caused by a higher cellular sensitivity of tissues in children with Down syndrome. However, whether differences in pharmacokinetics play a r...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.019778

    authors: Buitenkamp TD,Mathôt RA,de Haas V,Pieters R,Zwaan CM

    更新日期:2010-07-01 00:00:00

  • L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.

    abstract:BACKGROUND AND OBJECTIVE:Altered adhesive interaction between bone marrow (BM) stroma and progenitors in chronic myeloid leukemia (CML) may be in part caused by abnormal expression of cell adhesion molecules (CAMs) on malignant progenitor cells. Treatment of CML with interferon-a (IFN-a) re-establishes normal hemopoies...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Martín-Henao GA,Quiroga R,Sureda A,González JR,Moreno V,García J

    更新日期:2000-02-01 00:00:00

  • Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.

    abstract:BACKGROUND AND OBJECTIVE:Mantle cell lymphoma (MCL) is a separate histological and clinical entity recently recognized in the new revised European-American Lymphoma Classification. Little information exists regarding its therapy. We report the results of a retrospective study of 27 patients affected by MCL evaluating t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Bertini M,Rus C,Freilone R,Botto B,Calvi R,Novero D,Orsucci L,Vitolo U,Palestro G,Resegotti L

    更新日期:1998-04-01 00:00:00

  • Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.

    abstract::We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficac...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Baudo F,de Cataldo F,Gaidano G,Italian registry of acquired hemophilia.

    更新日期:2004-06-01 00:00:00

  • Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

    abstract::The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.188227

    authors: Liu A,Li S,Donnenberg V,Fu J,Gollin SM,Ma H,Lu C,Stolz DB,Mapara MY,Monaghan SA,Lentzsch S

    更新日期:2018-10-01 00:00:00

  • Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.

    abstract::In patients with low and intermediate risk myelodysplastic syndrome and deletion 5q (del(5q)) treated with lenalidomide, monitoring of cytogenetic response is mandatory, since patients without cytogenetic response have a significantly increased risk of progression. Therefore, we have reviewed cytogenetic data of 302 p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.026658

    authors: Göhring G,Giagounidis A,Büsche G,Hofmann W,Kreipe HH,Fenaux P,Hellström-Lindberg E,Schlegelberger B

    更新日期:2011-02-01 00:00:00

  • Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

    abstract:BACKGROUND:Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or specificity. DESIGN AND METHODS:We examined the potential of gene e...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.029660

    authors: Balgobind BV,Van den Heuvel-Eibrink MM,De Menezes RX,Reinhardt D,Hollink IH,Arentsen-Peters ST,van Wering ER,Kaspers GJ,Cloos J,de Bont ES,Cayuela JM,Baruchel A,Meyer C,Marschalek R,Trka J,Stary J,Beverloo HB,Pieters R

    更新日期:2011-02-01 00:00:00

  • Red blood cell metabolism in Rhesus macaques and humans: comparative biology of blood storage.

    abstract::Macaques are emerging as a critical animal model in transfusion medicine, because of their evolutionary similarity to humans and perceived utility in discovery and translational science. However, little is known about the metabolism of Rhesus macaque red blood cells (RBC) and how this compares to human RBC metabolism ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.229930

    authors: Stefanoni D,Shin HKH,Baek JH,Champagne DP,Nemkov T,Thomas T,Francis RO,Zimring JC,Yoshida T,Reisz JA,Spitalnik SL,Buehler PW,D'Alessandro A

    更新日期:2020-08-01 00:00:00

  • Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.

    abstract::We report results of a phase II trial of combination of melphalan, lenalidomide, and dexamethasone for the treatment of immunoglobulin light chain (AL) amyloidosis. The primary objectives were tolerability and hematologic response rate; secondary objectives were organ responses and survival. Treatment protocol consist...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.075192

    authors: Sanchorawala V,Patel JM,Sloan JM,Shelton AC,Zeldis JB,Seldin DC

    更新日期:2013-05-01 00:00:00

  • Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks.

    abstract::Plasma transfusion is indicated for replenishment of coagulative proteins to stop or prevent bleeding. In 2014, the Netherlands switched from using ~300mL fresh frozen plasma (FFP) units to using 200mL Omniplasma, a solvent/detergent treated pooled plasma (SD plasma), units. We evaluated the effect of the introduction...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.222083

    authors: Saadah NH,Schipperus MR,Wiersum-Osselton JC,van Kraaij MG,Caram-Deelder C,Beckers EAM,Leyte A,Rondeel JMM,de Vooght KMK,Weerkamp F,Zwaginga JJ,van der Bom JG

    更新日期:2020-04-01 00:00:00

  • Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients.

    abstract::One hundred thirty-three febrile episodes in 115 neutropenic patients with hematologic malignancies were empirically treated with ceftriaxone and amikacin in a single daily dose. An indwelling central venous catheter (CVC) was present in 44 cases. Septicemia was documented in 18 (41%) patients with CVC (13 gram-positi...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Martino P,Girmenia C,Raccah R,Micozzi A,Cimino G,Mandelli F

    更新日期:1990-01-01 00:00:00

  • Tetraploidy or near-tetraploidy clones with double 8;21 translocation: a non-random additional anomaly of acute myeloid leukemia with t(8;21)(q22;q22).

    abstract::We report on 6 patients with tetraploidy or near-tetraploidy acute myeloid leukemia (AML) with double t(8;21) (q22;q22) and review the literature on cases with the same cytogenetic abnormalities. Some common features were revealed by this analysis. ...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Xiao Z,Liu S,Liu X,Yu M,Hao Y

    更新日期:2005-03-01 00:00:00

  • High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis.

    abstract:BACKGROUND AND OBJECTIVES:High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) has proven to be superior to conventional chemotherapy in patients with chemosensitive relapse of aggressive non-Hodgkin's lymphoma (NHL). Therefore, HDT/ASCT was evaluated as part of first-line therapy. Several...

    journal_title:Haematologica

    pub_type: 杂志文章,meta分析

    doi:

    authors: Strehl J,Mey U,Glasmacher A,Djulbegovic B,Mayr C,Gorschlüter M,Ziske C,Schmidt-Wolf IG

    更新日期:2003-11-01 00:00:00

  • Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

    abstract:BACKGROUND:Many different techniques have been designed for the quantification of JAK2V617F allelic burden, sometimes producing discrepant results. DESIGN AND METHODS:JAK2V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specif...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.13486

    authors: Lippert E,Girodon F,Hammond E,Jelinek J,Reading NS,Fehse B,Hanlon K,Hermans M,Richard C,Swierczek S,Ugo V,Carillo S,Harrivel V,Marzac C,Pietra D,Sobas M,Mounier M,Migeon M,Ellard S,Kröger N,Herrmann R,Prchal JT

    更新日期:2009-01-01 00:00:00

  • HTLV-I positive adult T-cell leukaemia-lymphoma: report of a typical case from Italy.

    abstract::A case of acute adult T-cell leukemia-lymphoma (ATLL) was observed in northeast Italy, presenting with fever, lymphadenomegaly, splenomegaly, hypercalcemia and renal failure. Leukaemic cells were morphologically typical, expressed a T-cell CD4+ phenotype, did not display any helper functions, and grew in vitro under s...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Fanin R,Minutillo S,D'Agaro P,Raspadori D,Tassinari A,Tazzari P,Testoni N,Damiani D,Gallizia C,Michieli M

    更新日期:1990-07-01 00:00:00

  • Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.

    abstract::To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 month...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.11891

    authors: Yanada M,Takeuchi J,Sugiura I,Akiyama H,Usui N,Yagasaki F,Nishii K,Ueda Y,Takeuchi M,Miyawaki S,Maruta A,Narimatsu H,Miyazaki Y,Ohtake S,Jinnai I,Matsuo K,Naoe T,Ohno R,Japan Adult Leukemia Study Group.

    更新日期:2008-02-01 00:00:00

  • Hemoglobin sickle cell disease complications: a clinical study of 179 cases.

    abstract:BACKGROUND:Hemoglobin sickle cell disease is one of the most frequent hemoglobinopathies. Surprisingly, few studies have been dedicated to this disease, currently considered to be a mild variant of homozygous sickle cell disease. The aim of this study was to update our knowledge about hemoglobin sickle cell disease. D...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.055202

    authors: Lionnet F,Hammoudi N,Stojanovic KS,Avellino V,Grateau G,Girot R,Haymann JP

    更新日期:2012-08-01 00:00:00

  • Autoimmunity and the risk of myeloproliferative neoplasms.

    abstract::The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.020412

    authors: Kristinsson SY,Landgren O,Samuelsson J,Björkholm M,Goldin LR

    更新日期:2010-07-01 00:00:00

  • Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity.

    abstract:BACKGROUND:It has been shown that fludarabine (FLU) is superior to conventional treatment in B-CLL for rate and quality of response, leading to CR even at the molecular level. In this paper we report our preliminary results with this drug in B-CLL patients. METHODS AND PATIENTS:Twenty-seven B-CLL patients (16 refracto...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Spriano M,Clavio M,Carrara P,Canepa L,Miglino M,Pierri I,Celesti L,Rossi E,Vimercati R,Bruni R

    更新日期:1994-05-01 00:00:00